Octapharma opens €25 million recombinant research facility in Heidelberg
Octapharma AG today announces the opening of a €25 million research facility dedicated to recombinant protein drug development in Heidelberg, Germany. Octapharma Biopharmaceuticals GmbH is a subsidiary of Octapharma AG, one of the world’s largest providers of human therapeutic proteins and one of the first companies using recombinant technology from human cells. The investment into the state-of-the-art recombinant Research and Development center signifies Octapharma’s continued commitment to developing efficacious, safe and highly tolerable recombinant medicines. Octapharma’s unique approach, from human to human, sets the company apart from those recombinant products based on animal derived cell lines.
Octapharma Biopharmaceuticals GmbH was founded in 1997 in Munich. As the recombinant research arm of Octapharma grew it was evident that the original 1400 m² site, in the biotech research and innovation centre IZB, could not offer the space needed for future expansion. Although alternatives in Munich were considered, when Wolfgang Marguerre, founder and chairman of Octapharma AG, was shown Heidelberg Technology Park he knew this was the place to build. The new location places the company in the heart of a scientific cluster close to medical and clinical establishments including the German Cancer Research Center (the DKFZ) and Heidelberg University Hospital, one of the leading medical centers in Europe.
Dr. Ulrich Thibaut, Board Member R&D Octapharma AG, said “the building resembles a ship, with a glass bow, going forward into new frontiers. In many ways this reflects the work we are doing here, undertaking a journey of discovery. Our new location in Heidelberg will strengthen our footprint in one of the most important biotech clusters in Germany.”
The striking new 10,000 m² building was designed by local Heidelberg architectural firm Burger and Partner. Not only will the impressive building be home to innovative research in human recombinant technology, but also to the development of the clinical production of these new products. The 6 meter high space allows for the scaling up to 1000 litre fermenters for production. Currently employing 46 people, Octapharma Biopharmaceuticals now has laboratory and office space for up to 120 staff.
Wolfgang Marguerre said “the new home of Octapharma Biopharmaceuticals is in my hometown, only a few minutes from my birthplace and the school I attended as a boy. I feel very proud that we are focusing these key research activities in this excellent university city. The groundbreaking work being carried out here will have international reach.”
Carola Schröder, GM of Octapharma Biopharmaceuticals, said “through the use of human cell lines we aim to create more compatible medicines with improved tolerability and reduced immunogenicity. As a modern alternative to plasma products these innovative medicines will be used in the treatment of patients including those with haemophilia. One project in the preclinical stage uses this recombinant technology to develop supportive therapy to restore the immune system after tumour patients have undergone chemotherapy.”
To celebrate the opening of the state-of-the-art facility Octapharma brings Oktoberfest to Heidelberg in the form of a party to honour the Bavarian roots of many of the employees who moved from Munich to the new location in Heidelberg. Some 400 guests, including the Mayor of Heidelberg, are joining the Marguerre family to mark the beginning of a new era in Octapharma’s innovative research into recombinant technologies.
About Octapharma
Octapharma is one of the largest plasma human protein product manufacturers in the world. Our core business is the development, production and sale of premium human proteins from human plasma and human cell-lines. Octapharma employs almost 5,000 people in 28 countries with sales of approximately €1 billion. Patients in over 80 countries are treated with products in the following therapeutic areas:
• Haematology (coagulation disorders)
• Immunotherapy (immune disorders)
• Intensive Care and Emergency Medicine
Octapharma owns five state of the art production facilities in Austria, France, Germany, Sweden and Mexico. For more information visit www.octapharma.com
Contact:
Octapharma AG
Corporate Communications
Claudie Qumsieh
Tel:
+41 (55) 451 21 78
claudie.qumsieh@octapharma.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin Launches K Navigator, a Ground-breaking Agentic Co-pilot to Speed up Breakthroughs in Biomedical Research by 20x6.5.2025 06:15:00 CEST | Press release
K Navigator increases researcher productivity by 20x¹, accelerating biomedical breakthroughs and outperforming leading generalist LLMs Analyzes and visualizes multimodal patient data, plus exclusive access to MOSAIC Window, a subset of the world’s largest spatial omics dataset in oncology Built by biologists, for biologists. Free to use for academic researchers.² Owkin, a leading agentic AI company, has launched K Navigator, an AI-powered research co-pilot designed to revolutionize biomedical science. K Navigator is an agentic playground where researchers can explore, refine, and validate hypotheses, accelerating the quality and pace of their discoveries. With K Navigator, Owkin moves closer to its vision of developing the world’s first Biological Artificial Superintelligence (BASI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505282917/en/ K Navigator home screen. A single natural language interface - K Navigator enab
NIKE, Inc. Announces Senior Leadership Changes to Accelerate Growth and Drive Win Now Action Plan5.5.2025 22:15:00 CEST | Press release
Amy Montagne Becomes President, NikePhil McCartney Becomes EVP, Chief Innovation, Design & Product OfficerNicole Graham Becomes EVP, Chief Marketing OfficerTom Clarke Becomes Chief Growth Initiatives OfficerHeidi O’Neill to Retire NIKE, Inc. (NYSE:NKE) announced a series of strategic changes to its Senior Leadership Team (SLT), elevating experienced leaders to accelerate progress against its Win Now action plan to position the company for future growth. Elliott Hill, President and CEO, NIKE, Inc. and Heidi O’Neill, President of Consumer, Product, and Brand, have decided the Consumer, Product, and Brand leadership will now be divided into three distinct areas: Consumer and Sport, Marketing, and Product Creation, inclusive of Innovation and Design. These roles will now report directly to Hill. As a result of these changes O’Neill has decided to retire from Nike after 26 years. She will continue to serve in an advisory capacity until September 2025. “For nearly three decades, Heidi has be
LR Health & Beauty Once Again Demonstrates Its Expertise in Aloe Vera5.5.2025 16:24:00 CEST | Press release
The social commerce company develops a unique combination of Aloe Vera Gel and fermented Aloe LR Health & Beauty has been synonymous with the best Aloe Vera quality on the market for over 20 years, and continuously invests in new product innovations to take full advantage of the plant's range of beneficial properties. The majority of the over 60 products are developed and produced directly at the company headquarters in Ahlen. LR has now made a decisive breakthrough in skin care cosmetics with its unique combination of pure Aloe Vera leaf gel and fermented Aloe Vera. The care products with the highest Aloe Vera content therefore not only work in the upper and middle layers of the skin, but also unleash the full potential of Aloe Vera in the deeper layers. The effectiveness of this LR Aloe Via Magic Power Duo has been confirmed by the dermatological institute, Dermatest. All the products tested based on a combination of Aloe Vera Gel and fermented Aloe were awarded the 5-star "very good
MultiBank Group Signs Strategic Partnership With MAG to Tokenize $3 Billion Real Estate Assets5.5.2025 16:09:00 CEST | Press release
The largest tokenization initiative of its kind comes ahead of the $MBG token launch, paving the way for regulated digital access to prime property assets MultiBank Group, the world’s largest financial derivatives institution based in Dubai has signed a historic $3 billion tokenization agreement with MAG, the leading real estate developer in the UAE, and Mavryk, a leading blockchain innovator — marking the largest real-world asset (RWA) tokenization initiative globally to date. The initiative highlights the imminent launch of $MBG, the utility token at the core of MultiBank’s next-generation digital finance ecosystem. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505317631/en/ MultiBank Group Signs Strategic Partnership With MAG to Tokenize $3 Billion Real Estate Assets The partnership will bring MAG’s high-value real estate developments — The Ritz-Carlton Residences, Dubai, Creekside, which is part of the Keturah Resort
3Degrees Grows Carbon Asset Development Capabilities in Singapore5.5.2025 15:30:00 CEST | Press release
3Degrees will be expanding its carbon asset development capabilities in Singapore with plans to build a pipeline of high-integrity Article 6 carbon projects across Southeast Asia and beyond, supporting the region’s growing demand for trusted climate solutions. The expansion will be supported by the Singapore Economic Development Board (EDB)’s pilot Carbon Project Development grant that seeks to catalyze a new wave of early-stage carbon projects, aligned with Article 6 of the Paris Agreement. The initiative reinforces Singapore’s position as a global hub for high-integrity climate solutions and marks a key milestone in 3Degrees’ continued expansion in Asia Pacific. 3Degrees, a leading global climate solutions provider, announced today that it will be expanding its carbon asset development capabilities in Singapore. The move will see the company developing a pipeline of projects that are aligned with Article 6 of the Paris Agreement across Southeast Asia and beyond, supporting the region
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom